公开(公告)号：EP3388079A1

公开(公告)日：2018-10-17

申请号：EP18174337.8

申请日：2016-03-24

申请人： Immatics Biotechnologies GmbH

发明人： Mahr, Andrea ,  Stevermann, Lea ,  Weinschenk, Toni ,  Schoor, Oliver ,  Fritsche, Jens ,  Singh, Harpreet

IPC分类号： A61K39/00 ,  C07K14/47

CPC分类号： C07K14/70539 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：EP3322715A1

公开(公告)日：2018-05-23

申请号：EP15739551.8

申请日：2015-07-14

申请人： BioNTech AG ,  TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg- Universität Mainz gemeinnützige GmbH ,  JPT Peptide Technologies GmbH

发明人： SAHIN, Ugur ,  PLUM, Laura Maria ,  FIEDLER, Markus ,  DANESCHDAR, Matin ,  SCHMOLDT, Hans-Ulrich ,  REIMER, Ulf ,  SCHNATBAUM, Karsten

IPC分类号： C07K7/06 ,  A61K38/08 ,  C07K14/725

CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K14/7051 ,  C07K2319/00 ,  G01N2333/7051

摘要： The present invention provides molecules that mimic antigenic determinants of the CD3 (cluster of differentiation 3) T-cell co-receptor epsilon chain (CD3ε). These molecules compete with CD3ε for binding to a CD3ε binding domain, e.g. a CD3ε binding domain of an antibody, and are capable of detecting antibodies against CD3ε. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Additionally, they may serve as tools for anti-CD3ε antibody purification and the detection of anti-CD3ε antibodies in biological samples.

公开(公告)号：EP3277311A1

公开(公告)日：2018-02-07

申请号：EP16717271.7

申请日：2016-03-31

申请人： Technische Universität München

发明人： GERHARD, Markus ,  BUSCH, Dirk ,  DOESSINGER, Georg ,  SCHUMACHER, Antonius ,  LINNEMANN, Carsten

IPC分类号： A61K39/00 ,  A61K39/12 ,  C07K14/045 ,  C07K14/47 ,  C12N5/0783

CPC分类号： G01N33/57492 ,  A61K39/0011 ,  A61K39/0208 ,  A61K39/12 ,  A61K2039/5158 ,  C07K14/4748 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2710/16134 ,  C12Q1/6886 ,  C12Q2600/156 ,  G01N2333/7051 ,  G01N2333/70539

摘要： The present invention relates to a method for providing a neopeptide-specific T cell, wherein the neopeptide-specific T cell forms a complex having a half-life (T 1/2 ) of at least 50 s with a neopeptide-MHC monomer. The present invention further relates to a T cell obtainable by the method as well as a pharmaceutical composition comprising such T cells.

公开(公告)号：EP3262160A1

公开(公告)日：2018-01-03

申请号：EP16756351.9

申请日：2016-02-25

申请人： Biomagnetic Solutions LLC

发明人： LIBERTI, Paul, A. ,  KHRISTOV, Todor, R.

IPC分类号： C12N5/16 ,  C12N5/0789 ,  C07K16/00

CPC分类号： G01N33/56972 ,  C12N5/0636 ,  C12N2501/998 ,  G01N33/54326 ,  G01N33/54346 ,  G01N2333/7051 ,  G01N2333/70521

摘要： Methods are provided for the rapid and efficient separation of target bioentities.

公开(公告)号：EP3119902A4

公开(公告)日：2017-11-29

申请号：EP15765747

申请日：2015-03-18

申请人： APTEVO RES AND DEV LLC

发明人： SEWELL ELAINE ,  BLANKENSHIP JOHN ,  LOWE RICHARD

IPC分类号： C12P21/08 ,  A01N63/00 ,  A61K39/00 ,  A61K39/395 ,  C07K16/00 ,  C12N5/07 ,  G01N33/50

CPC分类号： G01N33/5011 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2896 ,  C07K16/3069 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/732 ,  G01N33/5014 ,  G01N33/505 ,  G01N2333/7051 ,  G01N2333/70596 ,  G01N2500/02 ,  G01N2500/10 ,  G01N2510/00

摘要： This disclosure provides a cell-based assay for testing the potency of multispecific binding molecules which specifically bind a T-cell antigen and a target antigen for redirected T-cell-mediated cellular cytotoxicity. The assay uses the TALL-104 T-cell line as effector cells, and provides a sensitive, specific, and reproducible method for ensuring that purity, activity, and stability of multispecific binding molecule batches can be measured for development, clinical trials, and commercial marketing.

公开(公告)号：EP3091998A1

公开(公告)日：2016-11-16

申请号：EP15700081.1

申请日：2015-01-08

申请人： Genmab A/S

发明人： BRINK, Edward Norbert Van Den ,  NEIJSSEN, Joost J. ,  LABRIJN, Aran Frank ,  MEESTERS, Joyce ,  SCHUURMAN, Janine ,  ALTINTAS, Isil ,  PARREN, Paul ,  RADEMAKER, Rik

IPC分类号： A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  C07K16/46

CPC分类号： C07K16/2809 ,  A61K2039/505 ,  C07K16/1063 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/32 ,  C07K16/4241 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/90 ,  C07K2317/92 ,  G01N33/6872 ,  G01N2333/7051

摘要： The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

公开(公告)号：EP3019622A2

公开(公告)日：2016-05-18

申请号：EP14822418.1

申请日：2014-07-11

申请人： Zymeworks Inc.

发明人： NG, Gordon, Yiu Kon ,  DIXIT, Surjit, Bhimarao ,  SPRETER VON KREUDENSTEIN, Thomas

IPC分类号： C12P21/08

CPC分类号： C07K16/2809 ,  A61K47/48561 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/90 ,  G01N33/6872 ,  G01N2333/70503 ,  G01N2333/7051

摘要： Bispecific antigen binding contructs are described that bind to CD3 and CD19 or CD20 antigens.

摘要翻译： 描述了结合CD3和CD19或CD20抗原的双特异性抗原结合构建体。

公开(公告)号：EP2235527B1

公开(公告)日：2015-06-24

申请号：EP08861905.1

申请日：2008-12-15

申请人： Transmedi SA

发明人： BIHAIN, Bernard ,  OGIER, Virginie ,  BRULLIARD, Marie

IPC分类号： G01N33/53 ,  G01N33/574

CPC分类号： G01N33/57484 ,  G01N2333/7051 ,  G01N2800/52 ,  G01N2800/56

公开(公告)号：EP2701737A4

公开(公告)日：2015-01-21

申请号：EP12777486

申请日：2012-04-27

申请人： SELECTA BIOSCIENCES INC

发明人： KISHIMOTO TAKASHI KEI ,  FRASER CHRISTOPHER ,  MALDONADO ROBERTO A

IPC分类号： A61K39/35 ,  A61K9/14 ,  A61K9/16 ,  A61K31/00 ,  A61K31/40 ,  A61K31/44 ,  A61K39/36 ,  A61P37/00

CPC分类号： A61K39/385 ,  A61K9/127 ,  A61K9/14 ,  A61K9/51 ,  A61K9/5115 ,  A61K9/5146 ,  A61K9/5153 ,  A61K31/192 ,  A61K38/13 ,  A61K38/1816 ,  A61K38/38 ,  A61K39/00 ,  A61K39/0008 ,  A61K39/001 ,  A61K39/35 ,  A61K39/36 ,  A61K47/50 ,  A61K47/52 ,  A61K47/544 ,  A61K47/593 ,  A61K47/643 ,  A61K47/69 ,  A61K47/6923 ,  A61K47/6929 ,  A61K47/6937 ,  A61K2039/5154 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/577 ,  B82Y5/00 ,  B82Y40/00 ,  G01N33/505 ,  G01N33/56972 ,  G01N2333/7051 ,  G01N2333/70514 ,  G01N2333/70517 ,  A61K2300/00

摘要： Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering B cell and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to reduce antigen-specific activation of innate immune cells.

公开(公告)号：EP2746393A1

公开(公告)日：2014-06-25

申请号：EP12803980.7

申请日：2012-06-20

申请人： International Institute of Cancer Immunology, Inc.

发明人： SUGIYAMA, Haruo

IPC分类号： C12N15/09 ,  C07K14/725 ,  C07K16/30 ,  C12M1/00 ,  C12N5/10 ,  C12Q1/04 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  C07K14/7051 ,  C07K16/2809 ,  C07K16/30 ,  C07K2317/34 ,  C07K2317/565 ,  C12Q1/686 ,  C12Q1/6881 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/56977 ,  G01N33/574 ,  G01N2333/7051

摘要： The invention provides the nucleotide sequence and amino acid sequence of the CDR3 domain of the T cell receptor (TCR) gene of a WT1-specific cytotoxic T cell (CTL) against WT1 protein. Also provided are a method for testing for and treating cancer using the nucleotide sequence and amino acid sequence, and a chip, primer set, kit, and device for testing for cancer comprising the nucleotide sequence and amino acid sequence.

摘要翻译： 本发明提供了针对WT1蛋白的WT1特异性细胞毒性T细胞（CTL）的T细胞受体（TCR）基因的CDR3结构域的核苷酸序列和氨基酸序列。 还提供了使用核苷酸序列和氨基酸序列测试和治疗癌症的方法，以及包含核苷酸序列和氨基酸序列的用于癌症检测的芯片，引物组，试剂盒和装置。